Revive Therapeutics closes second tranche of private placement for $91,400

Revive Therapeutics Ltd. (OTCQB: RVVTF) (CSE: RVV) announced the completion of a second tranche of its private placement, issuing 4,352,381 units at $0.021 per unit for gross proceeds of $91,400.

Each unit consists of one common share and one warrant. The warrants allow holders to purchase additional common shares at $0.05 each within 36 months of the closing date.

The company stated it will use proceeds for working capital and to pay certain trade payables. All securities issued are subject to a hold period expiring January 19, 2026.

The Toronto-based life sciences company previously announced the private placement on September 5, 2025, according to the press release.

You May Also Be Interested In